Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025
Eli Lilly and Company opened the week with a burst of dealmaking and Wall Street momentum. The pharma giant announced a rights deal for a pediatric blindness gene therapy from MeiraGTx, unveiled a new AI‑driven discovery partnership, and captured an analyst upgrade with a higher price target—moves that had LLY trading sharply higher intraday. Reuters+2 The MeiraGTx alliance hands Lilly a potential first‑in‑class therapy for LCA4 that, in a small study, has shown the ability to restore visual function in children born legally blind. Beyond the single asset, Lilly secures platform access—vector and riboswitch technologies—that could seed a broader ophthalmology pipeline. Strategically, this builds on Lilly’s Adverum acquisition in October for an intravitreal wet AMD gene therapy candidate, signaling a deliberate expansion into vision care alongside its metabolic crown jewels. BioPharma Dive+2Reuters+2
